Factor Related Apoptosis Ligand (FASL) Antibody Pair

Product specifications

Antibody Pairs

Factor Related Apoptosis Ligand (FASL)

Human

Detection Antibody Biotinilated

Sandwich

Dilute the Capture Antibody 125-fold with Coating Buffer.  Dilute the Biotin-Conjugated Detection Antibody 200-fold with Detection Antibody Diluent.  Optimal dilutions/concentrations should be determined by the end user.

5 × 96 tests

10 × 96 tests

Standard: Lyophilized--Liquid (Capture Antibody and Detection Antibody)

Reconstitute the standard with Standard Diluent. The volume, and therefore standard concentration, should be determined by the end user.

ELISA

The Capture and Detection Antibody both contain 0.1% sodium azide.

Please enquire.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

Tumor necrosis factor ligand superfamily member 6,APTL,FASL,CD178,CD95L,ALPS1B,CD95-L,TNFSF6,TNLG1A,APT1LG1,Apoptosis antigen ligand,Fas antigen ligand

Antibody Pair for FASLG

RUO

This antibody pair contains ( 5 x 96 det):    Detection:  50 µg  Capture:  200 µg  Standard:  2 µg

This product is for research use only.

Descripción

Fas Ligand (FASLG), also referred to as CD95L, is a type-II transmembrane protein belonging to the tumor necrosis factor (TNF) family. FASLG plays a pivotal role in regulating apoptosis, particularly in immune system homeostasis and cytotoxic T-cell-mediated killing. It binds to its receptor, Fas (CD95), triggering the formation of the death-inducing signaling complex (DISC) and initiating the caspase cascade, ultimately leading to programmed cell death. This pathway is crucial for eliminating autoreactive lymphocytes, maintaining immune tolerance, and resolving immune responses after infections. Dysregulation of FASLG-Fas signaling has been implicated in various pathological conditions, including autoimmune disorders, cancer, and chronic inflammatory diseases. In cancer, tumor cells often evade apoptosis by downregulating Fas or mutating components of the pathway. Conversely, overexpression of FASLG in the tumor microenvironment can contribute to immune evasion by inducing apoptosis in Fas-expressing tumor-infiltrating lymphocytes. Therapeutic strategies targeting FASLG or its signaling pathway are being explored for their potential in cancer immunotherapy, autoimmune disease modulation, and transplantation tolerance. Additionally, genetic polymorphisms in the FASLG gene have been associated with altered susceptibility to diseases, further highlighting its importance in immune regulation and disease pathology.

Related Products

Human FASL (Factor Related Apoptosis Ligand) ELISA Kit

Ver Producto

Mouse FASL/Faslg (Factor Related Apoptosis Ligand) ELISA Kit

Ver Producto

Porcine FASL/TNFSF6 (Factor Related Apoptosis Ligand) ELISA Kit

Ver Producto